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Abstract
Background: The safety and efficacy of chemotherapy for patients undergoing concomitant hemodialysis have not
been fully established and optimal doses of anti-cancer drugs and best timing of hemodialysis remains unclear.
Although chemosensitive cancers, such as germ cell tumors, treated with chemotherapy should have sufficient
dose intensity maintained to achieve the desired effect, many patients with cancer undergoing hemodialysis might
be under-treated because the pharmacokinetics of anti-cancer drugs in such patients remains unknown.
Case presentation: We describe a 31-year-old Japanese man with a mediastinal yolk sac tumor treated with
surgery followed by five cycles of chemotherapy containing cisplatin and etoposide while concomitantly
undergoing hemodialysis. The doses of these agents used in the first cycle were 50% of the standard dose of
cisplatin (10 mg/m2) and 60% of the standard dose of etoposide (60 mg/m2) on days 1 through to 5; the doses
were subsequently escalated to 75% with both agents. Hemodialysis was started 1 hour after infusions of these
agents. Severe hematological toxicities were observed despite successful treatment. During treatment with
concurrent hemodialysis, pharmacokinetic analysis of cisplatin was performed and its relationship with adverse
effects was assessed. Compared with patients with normal renal function, the maximum drug concentration was
higher, and concentration increased in the interval between hemodialysis and the subsequent cisplatin infusion,
resulting in a higher area under the curve despite a reduction in the dose to 75% of the standard regimen.
Conclusions: Because of the altered pharmacokinetics pharmacodynamics status of patients with renal dysfunction
undergoing hemodialysis, pharmacokinetics pharmacodynamics analysis is deemed to be helpful for effective and
safe management of chemotherapy in patients undergoing hemodialysis.
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Background
Germ cell tumors of extragonadal origin have been
reported to make up from 1 to 5% of all germ cell
tumors. The most common site is the mediastinum,
constituting 50 to 70% [1, 2]. In general, germ cell
tumors are sensitive to platinum-based chemotherapy
and patients have a favorable prognosis. However,
response of mediastinal non-seminomatous germ cell
tumors to therapy is less than favorable, so these tumors
have been classified into the poor prognosis group [3, 4].
It has been reported that 40 to 54% of patients with
mediastinal non-seminomatous germ cell tumor treated
with platinum-based chemotherapy followed by surgical
resection achieved long-term disease-free survival, but
patients who relapsed after initial treatment experienced
dismal outcomes with only 10% long-term survival
[5–7]. Therefore, it is important to accomplish successful
initial chemotherapy with an adequate dose.
Recently, the number of patients with end-stage renal
failure undergoing hemodialysis (HD) is increasing, and
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patients undergoing HD are potentially at high risk of
cancer [8]. However, the safety and efficacy of chemo-
therapy for patients undergoing concomitant HD have
not been fully established and optimal doses of anti-
cancer drugs and best timing of HD remains unclear.
Many patients with cancer undergoing HD might be
under-treated because the pharmacokinetics (PK) of
anti-cancer drugs in such patients remains unknown
and severe adverse effects are feared. However, chemo-
sensitive cancers such as germ cell tumors treated with
chemotherapy should have sufficient dose intensity
maintained to achieve the desired effect.
In this article, we report the case of a patient with
mediastinal yolk sac tumor who was successfully treated
with cisplatin and etoposide while concomitantly under-
going HD. We carried out a PK analysis of cisplatin as
part of a multicenter study and carefully considered the
relationship between adverse effects and blood concen-
tration of cisplatin.
Case presentation
A 31-year-old Japanese man was referred to our hospital
with renal dysfunction in April 2014. He had a history of
hypertension, hyperuricemia, and pituitary dwarfism, but
had not taken any medications. He was 159.4 cm in
height and 42.6 kg in weight (body surface area 1.398
m2). Initial blood tests showed anemia and renal dys-
function: blood urea nitrogen (BUN) 64.6 mg/dl, creatin-
ine (Cr) 5.66 mg/dl. A chest X-ray performed to evaluate
cardiomegaly revealed a mediastinal tumor in his right
thorax; a computed tomography (CT) scan confirmed
the mass to be a well-defined, homogeneous solid tumor
(53×35 mm) in his anterior mediastinum (Fig. 1). An
additional blood examination showed a high level, 322.6
ng/ml, of alpha-fetoprotein (AFP, normal <9 ng/ml), but
his beta-human chorionic gonadotropin (β-hCG) level
was within normal range. A CT-guided biopsy of the
mediastinal tumor showed the presence of tumor cells
with mixed sinusoidal-like, cystic, and papillary struc-
tures (Fig. 2a) and Schiller–Duval body (Fig. 2b), which
was positive by immunohistochemistry (IHC) for cyto-
keratin (CK) AE1/AE3 and AFP, and negative for placen-
tal alkaline phosphatase (PLAP), β-hCG, and CD30
(Fig. 2c, d), resulting in a diagnosis of primary medias-
tinal yolk sac tumor. Because of the complication of
end-stage renal insufficiency, surgery was selected as the
first treatment; following surgery, his AFP level de-
creased to the normal range. Subsequently, chemother-
apy with cisplatin (10 mg/m2) and etoposide (60 mg/m2)
was conducted daily from day 1 through to day 5. HD was
started 1 hour after infusions of these agents. Appendicitis
with grade 4 neutropenia occurred, so an appendectomy
was performed after the first cycle. In addition, grade 3
anemia and grade 4 neutropenia appeared under pro-
phylactic treatment with granulocyte-colony stimulating
factor (G-CSF). Because severe hematological toxicities
occurred, we conducted chemotherapy without dose
escalation on the second cycle. In contrast to the first
cycle, toxicities were admissible with 10 mg/m2 cisplatin
and 60 mg/m2 etoposide in the second cycle. To elevate
the dose intensity, the doses were escalated from the third
to the fifth cycles: cisplatin to 15 mg/m2 and etoposide to
75 mg/m2. Grade 4 neutropenia and thrombocytopenia as
well as grade 3 anemia were sustained over 7 days in spite
of prophylactic treatment with G-CSF. After five cycles of
chemotherapy, his AFP level remained in the normal
range and there has been no recurrence for 1 year.
During the third and fourth cycles, free cisplatin blood
concentrations were measured as part of a multicenter
study. Venous blood samples were collected five times
each day: (1) before cisplatin infusion, (2) immediately
after infusion, (3) before HD, (4) after HD, and (5) 4
hours after HD on days 1 to 5. In addition, blood was
collected before HD on day 8 once in each course
(Fig. 3). The time-concentration curve in the third cycle
is shown in Fig. 4. Our patient was administered 15 mg/
m2 cisplatin, and maximum concentration (Cmax) of
free cisplatin was 0.8 to 0.9 μg/mL. Just before treatment
with cisplatin, the concentration had not recovered to
the level observed after the previous HD. The concentra-
tion before infusion of cisplatin gradually increased each
day during the 5 days of treatment, and this phenomenon
was observed until 8 days after the start of chemotherapy.
During the fourth cycle, chemotherapy was administered
using the same doses used in the third cycle, and PK was
similar to that of the third cycle.
Discussion
In the International Germ Cell Consensus Classification
(IGCCC), primary mediastinal yolk sac tumor is classi-
fied into the poor prognosis group, and standard
Fig. 1 Computed tomography scan confirms a solid tumor (53×35
mm) in the anterior mediastinum (arrow)
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treatment consists of induction chemotherapy such as
BEP (bleomycin, etoposide, and cisplatin) or VIP (ifosfa-
mide, etoposide, and cisplatin) regimens followed by
radical operation [4]. In our case, it was considered likely
that standard chemotherapy would not be efficacious
because of end-stage renal insufficiency, so surgery was
selected as the first treatment so as not to miss the
opportunity for complete tumor resection. In addition,
bleomycin and active metabolite of ifosfamide are known
not to be sufficiently removed by HD, resulting in
enhanced toxicities such as pulmonary fibrosis, disturb-
ance of consciousness, and convulsions [9–14]. The-
refore, we selected combination chemotherapy with
cisplatin and etoposide, and doses of these agents used
in the first cycle were 50% of the standard dose of
cisplatin (10 mg/m2) and 60% of the standard dose of
etoposide (60 mg/m2) on days 1 through 5 according to
previous reports, and the doses were subsequently
escalated to 75% with both agents [14]. However, the
rationale for using these dosages, especially that of
Fig. 2 Pathological findings of computed tomography-guided biopsy specimen. a Tumor cells with mixed sinusoidal-like, cystic, and papillary
structures were observed (hematoxylin and eosin staining, ×20). b Schiller–Duval body was highlighted with white arrow (hematoxylin and eosin
staining, ×100). Immunohistochemical staining is positive for cytokeratin AE1/AE3 (×200) (c) and alpha-fetoprotein (d) (×200)
Fig. 3 Schedule of chemotherapy, hemodialysis, and blood sampling. In the third and fourth chemotherapy cycles, cisplatin (15 mg/m2) and
etoposide (75 mg/m2) was conducted daily from day 1 through to day 5. Hemodialysis was started 1 hour after infusions of these agents. Venous
blood samples were collected five times each day: (1) before cisplatin infusion, (2) immediately after infusion, (3) before hemodialysis, (4) after
hemodialysis, and (5) 4 hours after hemodialysis on days 1 to 5. In addition, blood was collected (6) before hemodialysis on day 8 once in each
course. CDDP cisplatin, ETP etoposide, HD hemodialysis
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cisplatin, has not been elucidated because of a paucity of
PK studies involving patients with HD. Froehner et al.
reported that they started the treatment from 50%
reduction of cisplatin according to guidelines on testicu-
lar cancer, and then escalated to 100% of standard dose
after monitoring adverse effects [14].
In this case, we obtained PK results for cisplatin dur-
ing cycles 3 and 4 in cooperation with Kyoto University.
The findings are as follows, compared with patients with
normal renal function administered 100% standard doses
of cisplatin [15]: (1) the Cmax of free cisplatin was
higher, and (2) concentration gradually increased after
HD up to the subsequent infusion of cisplatin (Fig. 4).
The higher Cmax might be related to our patient’s low
volume of distribution caused by pituitary dwarfism
rather than renal insufficiency. Immediately after HD,
the concentrations were lower, equivalent to those in
patients with normal renal function based on previous
reports [15]. However, his free cisplatin concentration
rose 4 hours after HD, and gradual accumulation of free
cisplatin was observed up until the subsequent treat-
ment with cisplatin. Pronounced elevation of free cis-
platin concentration may be due to redistribution from
peripheral tissues and reduced excretion of free cisplatin,
resulting in an elevated area under the curve (AUC) of
free cisplatin leading to severe hematological toxicity
[15–18]. Although nephrotoxicity has not been thought
to be a limitation in HD patients, dose-related adverse
effects are often observed [19], and dose reduction is
inevitable just as in our case. Because of the altered PK
pharmacodynamics (PD) status of patients with renal
dysfunction undergoing HD, determination of cisplatin
dosage should be based on monitored concentration to
conduct effective and safe chemotherapy.
Conclusions
Malignancies sensitive to chemotherapy require careful
maintenance of dose intensity, but this should be per-
formed safely. PK analysis is deemed to be useful for
appropriate chemotherapy in patients undergoing HD.
Additional evidence from other similar patients is needed
to establish suitable chemotherapy regimens for patients
with concomitant renal insufficiency.
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